TrialNature communications2025

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

Omar Nadeem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.